Skip to main content

Table 6 Serious adverse events (Safety Set)

From: Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study

 

JTA-100/2a

JTA-200/2a

JTA-200/4a

referencea

 

m

n (%)

m

n (%)

m

n (%)

m

n (%)

At least one serious AE

4

4 (9.8)

5

2 (4.9)

1

1 (2.4)

1

1 (2.4)

Gastrointestinal Disorders

2

2 (4.9)

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

 Barrett’s Esophagus

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

 Diarrhea

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

 Hernial Eventration

0

0 (0.0)

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

Infections and Infestations

0

0 (0.0)

3

1 (2.4)

1

1 (2.4)

0

0 (0.0)

 Osteomyelitis Acute

0

0 (0.0)

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

 Osteomyelitis Chronic

0

0 (0.0)

2

1 (2.4)

0

0 (0.0)

0

0 (0.0)

 Pneumonia

0

0 (0.0)

0

0 (0.0)

1

1 (2.4)

0

0 (0.0)

Injury, Poisoning and Procedural Complications

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

1

1 (2.4)

 Alcohol Poisoning

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

1

1 (2.4)

Musculoskeletal and Connective Tissue Disorders

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

 Arthralgia

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps)

0

0 (0.0)

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

 Squamous Cell Carcinoma of Lung

0

0 (0.0)

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

Reproductive System and Breast Disorders

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

 Rectocele

1

1 (2.4)

0

0 (0.0)

0

0 (0.0)

0

0 (0.0)

  1. AE adverse event, m number of serious adverse events, JTA-100/2 group of patients receiving an injection of JTA-004 with 100 μg clonidine and 20 mg hyaluronic acid, JTA-200/2 group of patients receiving an injection of JTA-004 with 200 μg clonidine and 20 mg hyaluronic acid, JTA-200/4 group of patients receiving an injection of JTA-004 with 200 μg clonidine and 40 mg hyaluronic acid, n number of patients with at least one serious AE, N total number of patients; reference, group of patients receiving an injection of the reference treatment (hylan G-F 20); %, (n row / N group) × 100. aN = 41 in each group